ACKRELL CAPITAL CHAPTER IV_ U.S. Legal Landscape Outlook Development (1) does not require any change in federal law or radical departure from prior federal policy, but merely requires a redirection of FDA and DEA policies and practices. Developments (2) and (3) also do not require a fundamental change in federal law. In this sense, developments (1)—(3) largely reflect incremental developments within the existing legal environment. For example, eight state legislatures are expected in 2018 to introduce ballot measures or explore regulatory frameworks for recreational cannabis (Arizona, Delaware, Florida, Michigan, New Jersey, Ohio, Rhode Island and Vermont). Three other states (Missouri, Oklahoma and Wyoming) are expected to enact medical can- nabis laws in 2018. And as discussed previously, many observers expect that in 2018, the FDA will approve a cannabis-derived pharmaceutical for the first time. Developments (4)—(6) require more fundamental changes in federal laws and policies. We do not expect developments (4), (5) or (6) to occur during the current presidential term, but we believe that there is a reasonable chance development (4) could begin within the next five years and development (5) could occur within two years thereafter. In total, we believe it could take up to 10 years or more before the federal legalization process reaches development (6) and cannabis becomes fully legal under federal law. We believe that cannabis will become federally legal when American voters demand it. Develop- ments (1)—(5) are not required precursors to federal legalization, and either the U.S. Congress or the DEA could initiate development (6) at any time. We believe that either the Congress or the DEA is more likely to take such a step in an environment where developments (1)—(5) have progressed, but there are signs that pressure from American voters may be mounting for the federal government to act more quickly. According to Gallup, the percentage of Americans who suppo